QIAGEN’s role in the initiative is to develop an easy-to-use, portable molecular testing device that can perform diagnostic tests in the field, far from hospital or laboratory infrastructure. This task also encompasses the creation of a corresponding assay technology suited for use in low-resource settings. This project is part of the technology development phase of the POC Dx initiative, which will then integrate successful technologies into a multifunctional point-of-care platform.  

 

“The new low-cost portable testing devices currently under development are intended to enable reliable, quick diagnosis and timelier treatment of patients,” said Dr. Ellen Sheets, chief medical officer of QIAGEN, in a statement. “We believe that modern diagnostic technologies can have a very significant positive impact on developing countries, helping to save lives, reduce economic impacts, and curtail the spread of infectious diseases.”